The News Review:
- Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …
- Growing Midwestern Clinical Research rganization Selects mniComm …
- Nanoparticle-delivered ‘Suicide’ Genes Slowed varian Tumor Growth
- Harbin doctor speaks to state officials about clinical research
- Algoma U NSM to discuss Clinical Research Institute
- MNDAY: HAGAN T ADDRESS NC SHERIFF’S ASSCIATIN DISCUSS …
Invitrogen Launches Biomarker Tool for Pre-Clinical Research into …
Business Wire (press release)
Shames Assistant Professor of Surgery Division of Transplant Surgery at the Medical College of Wisconsin “Development of a non-invasive test that could help differentiate between acute renal injury rejection and infection would satisfy a critical unmet need in transplantation. A biomarker test that can accomplish this would be of extreme importance in pre-clinical kidney transplantation research. ” Jim Janicki Vice President and General Manager of Life Technologies’ Transplantation Diagnostics Business “The launch of the PlexMark assay represents the continued expansion of our pre-clinical research business. We are excited about the non-invasive and cost-effective nature of PlexMark and anticipate that research clinicians will want to utilize this product to better understand immunosuppression as it relates to whole kidney function. ” Resources.
Growing Midwestern Clinical Research rganization Selects mniComm …
PR Newswire (press release)
(TC Bulletin Board: MCM) a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that a growing US Clinical Research rganization (CR) has selected mniComm to provide eClinical solutions in connection with two of the CR’s Phase IV studies covering approximately 27 sites and more than 700 subjects. Additional details were not disclosed. “We are pleased to have been selected by this CR to provide eClinical solutions for these important Phase IV studies” said Cornelis F. Wit mniComm’s President and CE.
Nanoparticle-delivered ‘Suicide’ Genes Slowed varian Tumor Growth
Science Daily (press release)
an associate editor of Cancer Research and associate director for clinical research at the Greenebaum Cancer Center at the University of Maryland said this report illustrates significant progress in targeted therapy. "In oncology we have been studying ways to kill tumors for a long time but much of this has run up against the real estate principle of location location location" he said. "In other words an effective therapy is not effective if it cannot get to the target. "Sausville said a major accomplishment of this research is the multiple ways it can target ovarian cancer cells as scientists were able to deliver diphtheria toxin genes using a nanoparticle to the actual tumor site (peritoneum) with a basis for selective activity in the cancer cells (how the toxin genes were regulated once inside the cells). "A real plus of a cancer therapy like this is not just the functionality of the nanoparticle construct molecule but the ability to deliver the toxin to the tumor cells" said Sausville who agrees that inception of clinical trials could be just 18 months away.
Related from Gxy988: Anti-tumor effect of Liqi a traditional Chinese medicine …
Harbin doctor speaks to state officials about clinical research
Rome News Tribune
Peller and Mary Waters International Trade Specialist with the Georgia Department of Economic Development. Peller a rheumatologist at Harbin Clinic recently spoke to state officials about Harbin?s clinical research and its significance to patients and physicians. He emphasized the role the clinic plays in participating in trials. Harbin currently has 11 ongoing pharmaceutical device and registry studies in which approximately 420 patient subjects participate. These are in the areas of osteoarthritis rheumatoid arthritis gout recurrent ovarian cancer cardiology devices breast implants and acute coronary syndrome. Peller has been involved in 40 clinical trials in his 24 years of practice since joining Harbin Clinic in 1985.
Algoma U NSM to discuss Clinical Research Institute
Sault Star
The partnership is to focus on life sciences research sharing resources and expertise. It’s premature to determine whether the document will be finalized on that date Perlini said but “the university is optimistic we can come to an understanding. “He said the Clinical Research Institute is a priority in both NSM’s medical school initiative and 2006-2009 strategic plan. The clinical research institute has also been articulated in the school’s one-year bridging document as something they want to advance he said. “Starting a medical school is a monumental enterprise and it has specific curriculum issues and social accountability issues it has to deal with in terms of health care practices in Northern ntario” Perlini said. “Some initiatives may not get advanced as quickly as others. “Council passed a resolution Monday that endorsed NSM’s strategic plan that includes the development of a clinical research business plan.
MNDAY: HAGAN T ADDRESS NC SHERIFF’S ASSCIATIN DISCUSS …
Trading Markets (press release)
Hagan (D-NC) will Monday address the NC Sheriff’s Association in Raleigh. She will also attend a ribbon cutting ceremony at the National Institute of Environmental Health Sciences for a new Clinical Research Unit in RTP.
